Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Olga O. Pozdnyakova, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Olga Pozdnyakova and Robert Hasserjian.
Connection Strength

3.815
  1. The importance of central pathology review in international trials: a comparison of local versus central bone marrow reticulin grading. Leukemia. 2015 Jan; 29(1):241-4.
    View in: PubMed
    Score: 0.606
  2. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms. Mod Pathol. 2014 Nov; 27(11):1447-54.
    View in: PubMed
    Score: 0.591
  3. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome. Blood Adv. 2019 11 12; 3(21):3322-3332.
    View in: PubMed
    Score: 0.217
  4. Gene expression profiling distinguishes prefibrotic from overtly fibrotic myeloproliferative neoplasms and identifies disease subsets with distinct inflammatory signatures. PLoS One. 2019; 14(5):e0216810.
    View in: PubMed
    Score: 0.210
  5. A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome. Am J Hematol. 2018 08; 93(4):504-510.
    View in: PubMed
    Score: 0.192
  6. Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica. 2018 04; 103(4):626-633.
    View in: PubMed
    Score: 0.191
  7. JAK2, CALR, MPL and ASXL1 mutational status correlates with distinct histological features in Philadelphia chromosome-negative myeloproliferative neoplasms. Haematologica. 2018 02; 103(2):e63-e68.
    View in: PubMed
    Score: 0.189
  8. Ring chromosome in myeloid neoplasms is associated with complex karyotype and disease progression. Hum Pathol. 2017 10; 68:40-46.
    View in: PubMed
    Score: 0.186
  9. NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. Am J Hematol. 2017 Jul; 92(7):E123-E124.
    View in: PubMed
    Score: 0.183
  10. Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Mod Pathol. 2016 10; 29(10):1221-31.
    View in: PubMed
    Score: 0.172
  11. Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category. J Clin Pathol. 2017 Feb; 70(2):109-115.
    View in: PubMed
    Score: 0.172
  12. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis. J Transl Med. 2015 Sep 10; 13:294.
    View in: PubMed
    Score: 0.163
  13. Prior cytopenia predicts worse clinical outcome in acute myeloid leukemia. Leuk Res. 2015 Oct; 39(10):1034-40.
    View in: PubMed
    Score: 0.160
  14. Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Mod Pathol. 2015 Jul; 28(7):965-76.
    View in: PubMed
    Score: 0.159
  15. Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms. Clin Lymphoma Myeloma Leuk. 2015 May; 15(5):253-61.
    View in: PubMed
    Score: 0.154
  16. Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML. Blood Adv. 2021 06 08; 5(11):2539-2549.
    View in: PubMed
    Score: 0.061
  17. A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML. Blood Adv. 2021 04 27; 5(8):2279-2283.
    View in: PubMed
    Score: 0.060
  18. Multiparametric in situ imaging of NPM1-mutated acute myeloid leukemia reveals prognostically-relevant features of the marrow microenvironment. Mod Pathol. 2020 07; 33(7):1380-1388.
    View in: PubMed
    Score: 0.055
  19. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms. Hum Pathol. 2019 04; 86:1-11.
    View in: PubMed
    Score: 0.051
  20. Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome. Leuk Lymphoma. 2017 03; 58(3):569-577.
    View in: PubMed
    Score: 0.043
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.